Open Targets Platform: supporting systematic drug–target identification and prioritisation. Issue Volume 49:Issue D1(2021) (16th November 2020)

• Record Type: Journal Article
• Authors: Ochoa, David; Hercules, Andrew; Carmona, Miguel; Suveges, Daniel; Gonzalez-Uriarte, Asier; Malangone, Cinzia; Miranda, Alfredo; Fumis, Luca; Carvalho-Silva, Denise; Spitzer, Michaela; Baker, Jarrod; Ferrer, Javier; Raies, Arwa; Razuvayevskaya, Olesya; Faulconbridge, Adam; Petsalaki, Eirini; Mutowo, Prudence; Machlitt-Northen, Sandra; Peat, Gareth; McAuley, Elaine; Ong, Chuang Kee; Mountjoy, Edward; Ghoussaini, Maya; Pierleoni, Andrea; Papa, Eliseo; Pignatelli, Miguel; Koscielny, Gautier; Karim, Mohd; Schwartzentruber, Jeremy; Hulcoop, David G; Dunham, Ian; McDonagh, Ellen M;
• Is Part Of: Nucleic acids research. Volume 49:Issue D1(2021)
• Page Start: D1302
• Page End: D1310
• Publication Date: 2020-11-16
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkaa1027
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: The Open Targets Platform (https://www.targetvalidation.org/ ) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.